Moderate, active Crohn´s Disease

Drug	Drug Name	Drug Description
DB14762	Risankizumab	An interleukin-23 antagonist used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease in adults.
DB15091	Upadacitinib	An oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies.
DB05679	Ustekinumab	A targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.

Drug	Drug Name	Target	Type
DB14762	Risankizumab	Interleukin-23	target
DB15091	Upadacitinib	Tyrosine-protein kinase JAK1	target
DB15091	Upadacitinib	Cytochrome P450 3A4	enzyme
DB15091	Upadacitinib	Cytochrome P450 2D6	enzyme
DB15091	Upadacitinib	P-glycoprotein 1	transporter
DB15091	Upadacitinib	ATP-binding cassette sub-family G member 2	transporter
DB15091	Upadacitinib	Solute carrier organic anion transporter family member 1B1	transporter
DB05679	Ustekinumab	Interleukin-12 subunit beta	target
DB05679	Ustekinumab	Interleukin-23	target

Drug	Drug Name	Phase	Status	Count